Jasper Ridge Partners L.P. Boosts Holdings in Nevro Corp. (NVRO)

Jasper Ridge Partners L.P. boosted its position in Nevro Corp. (NYSE:NVRO) by 2.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,016 shares of the medical equipment provider’s stock after purchasing an additional 693 shares during the quarter. Jasper Ridge Partners L.P. owned approximately 0.09% of Nevro Corp. worth $2,364,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVRO. Ameritas Investment Partners Inc. boosted its position in shares of Nevro Corp. by 17.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $181,000 after buying an additional 358 shares during the last quarter. PNC Financial Services Group Inc. purchased a new stake in shares of Nevro Corp. during the second quarter valued at $190,000. US Bancorp DE boosted its position in shares of Nevro Corp. by 412.4% during the second quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 2,099 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Nevro Corp. during the third quarter valued at $211,000. Finally, Prudential Financial Inc. boosted its position in shares of Nevro Corp. by 13.8% during the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock valued at $214,000 after buying an additional 350 shares during the last quarter.

Shares of Nevro Corp. (NVRO) traded up $1.94 during trading hours on Monday, reaching $80.71. The company’s stock had a trading volume of 461,300 shares, compared to its average volume of 511,519. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.81 and a current ratio of 8.78. Nevro Corp. has a fifty-two week low of $65.82 and a fifty-two week high of $99.63.

Nevro Corp. (NYSE:NVRO) last announced its earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. Nevro Corp. had a negative return on equity of 17.27% and a negative net margin of 14.09%. The business had revenue of $82.26 million for the quarter, compared to analysts’ expectations of $80.50 million. During the same period last year, the firm posted ($0.14) earnings per share. The business’s revenue for the quarter was up 35.0% on a year-over-year basis. equities analysts anticipate that Nevro Corp. will post -1.27 EPS for the current year.

In other news, Director Michael F. Demane sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $87.73, for a total value of $2,193,250.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Wilfred E. Jaeger sold 52,520 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $86.11, for a total value of $4,522,497.20. Following the completion of the transaction, the director now directly owns 1,518 shares in the company, valued at approximately $130,714.98. The disclosure for this sale can be found here. Insiders sold 115,987 shares of company stock worth $10,099,176 in the last ninety days. Corporate insiders own 9.10% of the company’s stock.

NVRO has been the topic of several recent analyst reports. Northland Securities reaffirmed a “buy” rating and set a $96.00 price objective on shares of Nevro Corp. in a research report on Tuesday, November 7th. Zacks Investment Research raised Nevro Corp. from a “strong sell” rating to a “buy” rating and set a $96.00 price objective on the stock in a research report on Wednesday, August 2nd. BMO Capital Markets reissued a “buy” rating and issued a $106.00 target price on shares of Nevro Corp. in a research report on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and issued a $120.00 target price on shares of Nevro Corp. in a research report on Sunday, October 8th. Finally, TheStreet raised Nevro Corp. from a “d+” rating to a “c-” rating in a research report on Monday, November 6th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $100.00.

COPYRIGHT VIOLATION WARNING: This report was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/11/20/jasper-ridge-partners-l-p-boosts-holdings-in-nevro-corp-nvro.html.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply